Uteroplacental insufficiency down regulates insulin receptor and affects expression of key enzymes of long-chain fatty acid (LCFA) metabolism in skeletal muscle at birth

1475-2840-7-14 1475-2840 Original investigation Uteroplacental insufficiency down regulates insulin receptor and affects expression of key enzymes of long-chain fatty acid (LCFA) metabolism in skeletal muscle at birth Germani Daniela germani@med.uniroma2.it Puglianiello Antonella apuglianiello@med.uniroma2.it Cianfarani Stefano stefano.cianfarani@uniroma2.it

Department of Public Health and Cell Biology, Tor Vergata University, 00133 Rome, Italy

Cardiovascular Diabetology 1475-2840 2008 7 1 14 http://www.cardiab.com/content/7/1/14 18485240 10.1186/1475-2840-7-14 18 4 2008 18 5 2008 18 5 2008 2008 Germani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Epidemiological studies have revealed a relationship between early growth restriction and the subsequent development of insulin resistance and type 2 diabetes. Ligation of the uterine arteries in rats mimics uteroplacental insufficiency and serves as a model of intrauterine growth restriction (IUGR) and subsequent developmental programming of impaired glucose tolerance, hyperinsulinemia and adiposity in the offspring. The objective of this study was to investigate the effects of uterine artery ligation on the skeletal muscle expression of insulin receptor and key enzymes of LCFA metabolism.

Methods

Bilateral uterine artery ligation was performed on day 19 of gestation in Sprague-Dawley pregnant rats. Muscle of the posterior limb was dissected at birth and processed by real-time RT-PCR to analyze the expression of insulin receptor, ACCα, ACCβ (acetyl-CoA carboxylase alpha and beta subunits), ACS (acyl-CoA synthase), AMPK (AMP-activated protein kinase, alpha2 catalytic subunit), CPT1B (carnitine palmitoyltransferase-1 beta subunit), MCD (malonyl-CoA decarboxylase) in 14 sham and 8 IUGR pups.

Muscle tissue was treated with lysis buffer and Western immunoblotting was performed to assay the protein content of insulin receptor and ACC.

Results

A significant down regulation of insulin receptor protein (p < 0.05) and reduced expression of ACS and ACCα mRNA (p < 0.05) were observed in skeletal muscle of IUGR newborns. Immunoblotting showed no significant change in ACCα content.

Conclusion

Our data suggest that uteroplacental insufficiency may affect skeletal muscle metabolism down regulating insulin receptor and reducing the expression of key enzymes involved in LCFA formation and oxidation.

Background

Uteroplacental insufficiency resulting in fetal growth retardation is a common complication of pregnancy and a significant cause of perinatal morbidity and mortality. Epidemiologic studies in humans have shown that impaired intrauterine growth is associated with an increased incidence of insulin resistance, type 2 diabetes, and cardiovascular disease in the adult 123456. These observations have led to the hypothesis that metabolic and cardiovascular disease in adulthood arises in utero, in part, as a result of changes in the development of key endocrine and metabolic pathways during suboptimal intrauterine conditions associated with impaired fetal growth. This hypothesis has been tested experimentally in a number of species, using a range of techniques to impair fetal growth. Inducing intrauterine growth retardation (IUGR) by placental insufficiency or by undernutrition, stress, or hormone treatment of the mother leads to endocrine and metabolic alterations in the adult offspring in several species 7. However, the mechanisms by which an abnormal uterine milieu leads to the development of diabetes in adulthood are not known. To investigate potential sequelae of IUGR and the underlying mechanisms, ligation of the uterine arteries in rats has been used as an animal model of uteroplacental insufficiency leading to growth retarded fetuses with a metabolic profile very similar to that of IUGR human fetuses 89. We have recently shown that uteroplacental insufficiency, obtained by uterine artery ligation, which leads to IUGR pups, affects the expression of specific hypothalamic lipid sensing genes such as the CPT1 isoform C, and acetyl-CoA carboxylase (ACC) isoforms alpha and beta 10.

Insulin resistance and type 2 diabetes are characterized by hyperglycemia with hyperinsulinemia, a reduced ability to oxidize fat, and an accumulation of fat within skeletal muscle 1112. This increase in muscle fat content is highly associated with insulin resistance 1314. Recently, perturbed skeletal muscle insulin signaling has been reported in adult growth restricted rats 15.

In this study we focused on the hypothesis that uteroplacental insufficiency may affect skeletal muscle metabolic pathways altering the expression of insulin receptor and of key enzymes of intramuscular lipid metabolism.

Methods

Animal model

Time-dated Sprague-Dawley pregnant rats (Harlan Sprague Dawley, Inc.) were individually housed under standard conditions and allowed free access to standard chow and water. On day 19 of gestation (term is 22 days) the maternal rats were anesthetized with intramuscular injections of xylazine (8 mg/Kg) and ketamime (40 mg/kg) (Sigma-Aldrich, St. Louis, MO), and the abdomen was opened along the midline. Suture was placed around both uterine arteries, then either tied or withdrawn before closing the abdomen 89. Dams recovered quickly from uterine artery ligation (n = 4) and sham procedures (n = 4), and resumed feeding the same day. After recovery, rats had ad libitum access to food and water. The pregnant rats were allowed to deliver spontaneously and at birth pups were weighted and killed by cervical dislocation. Posterior limb skeletal muscle tissue was immediately harvested and frozen in liquid nitrogen and stored at -80°C. 14 sham and 8 IUGR rats from different litters were tested. All procedures complied with Italian regulations for laboratory animal care, according to the guidelines and under supervision of the Animal Technology Station, Interdepartmental Service Center, Tor Vergata University, Rome, Italy.

Plasma assays

At birth, 14 SHAM and 8 IUGR pups were decapitated, blood was collected and centrifuged at 1900 × g at 4°C for 10 min, and plasma was stored at -80°C. Glucose and insulin concentrations were measured.

Glucose was determined using a colorimetric commercial kit (SigmaChemical Co.). Plasma insulin concentrations were measured in duplicate by a rat/mouse insulin ELISA kit, using rat insulin as the standard (Linco Research, St. Charles, MO) according to the manufacturer's instructions. The intraassay CV was 1.2–8.4%, the interassay CV was 6.0–17.9%, and the sensitivity limit was 0.2 ng/mL.

RNA isolation and cDNA synthesis

Total RNA was extracted using TriPure (Roche Applied Science) according to the manufacturer's instructions and quantified in duplicate using ultraviolet absorbance at 260 nm. Gel electrophoresis confirmed the integrity of the samples. 1 μg RNA, pretreated with RNase free DNase (Invitrogen Co.) was transcribed into the complementary DNA using the High-Capacity cDNA Archive Kit (Applied Biosystems) in a final volume of 50 μl following the manufacturer's protocol. To minimize variation in the reverse transcription reaction, all RNA samples from a single experimental setup were reverse transcribed simultaneously.

Real-time RT-PCR

We explored the expression of key enzymes that regulate fatty acid metabolism in the muscle. Real-time RT-PCR was performed on an ABI PRISM 7300 Sequencer Detector (Applied Biosystems). PCR primers and TaqMan probes to amplify and detect ACCα, ACCβ, ACS, AMPK, CPT1B, MCD, Insulin receptor and the housekeeping gene 18S were commercially available as inventoried assay (Assay-on-demand Gene Expression Product; Applied Biosystems).

Prior to performing real-time PCR, primer and probe concentrations were determined to demonstrate their specificity and optimal reaction condition. 18S was used as an internal control for differences in cDNA loading. Before the use of 18S as a control, parallel serial dilution of cDNA were quantified to prove the validity of using 18S as an internal control.

The real-time RT-PCR amplification was performed in skeletal muscle tissues from fourteen SHAM and eight IUGR rats. Experiments were performed in triplicate using 96-well tray and optical adhesive covers (Applied Biosystems) in a final reaction mixture of 20 μl containing 3 μl of undiluted cDNA. Real-time PCR was performed using Platinum Quantitative PCR SuperMix-UDG with ROX (Invitrogen Co.). The cycling consisted of 2 min at 50°C, 2 min at 95°C followed by 40 cycles of 95°C for 15 sec and 60°C for 45 sec. Determination of reaction efficiency was routinely used as an internal quality control for adequate assay performance. Crossing of threshold (Ct) values obtained for the target gene were normalized against each individual 18S value which was run in the same well of the real time RT-PCR run. Relative quantification of PCR products was performed using Relative Quantification Study software (Applied Biosystems). Results are expressed in raw relative quantification (RQ) ± standard errorrs.

Western immunoblotting

Tissues were homogenized in ice with lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 10 mM NaF, 1 mM Na₃VO₄, 10% glycerol, 0.5% Triton ×-100, 5 mM EDTA, 10 μl/ml cocktail protease inhibitors). Lysates were clarified by centrifugation at 13,000 g (30 minutes, 4°C), and protein concentration in the supernatant were determined by the Bradford assay (Bio-Rad Laboratories, CA, USA) using bovine serum albumin as a standard. Eighty micrograms of the extracted proteins were separated by SDS-PAGE on 3–8% Tricine gel (Bio-Rad Laboratories, CA, USA) and blotted onto ECL nitrocellulose membrane (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK). The filter was blocked with 5% non-fat dry milk in TBS-0.1% Tween 20 and then incubated with ACC rabbit polyclonal antibody (Cell Signaling Technology Inc. Danvers, MA) and insulin-Rβ rabbit polyclonal antibody (Santa Cruz). After several washes in PBS-0.1% Tween 20, horseradish peroxidase-conjugated secondary antibody (1:5,000) (Amersham) was added for 1 hour at RT. The labelled bands were detected using Amersham ECL western blotting system according to manufacturer's specifications. After protein detection, membranes were stripped with Restore Western Blot Stripping Buffer (Pierce, Rockford IL) and re-blotted with rabbit HRP-conjugated actin antibody (1:1000) (Santa Cruz). Densitometry analysis of bands was performed using a Image Quant 5 software (Molecular Dynamics).

Statistical analysis

Statistical analysis was performed using Sigma Plot for Windows Version 13.0 (SPSS, Inc, Chicago, IL, USA). Differences in gene expression between sham and IUGR rats were analyzed with one-way ANOVA. Differences between means from plasma assays and densitometric analyses were assessed by unpaired two-tailed t test. Differences were considered statistically significant at p < 0.05.

Results

Animal weights and metabolic profile

Birth weights of IUGR animals were significantly lower than those of controls (SHAM) (mean weight ± SD: 4.0 ± 0.57 versus 6.5 ± 0.32 g, p < 0.001). No significant differences were observed in blood glucose (63.9 ± 13 vs 62.9 ± 21.5 mg/dL) and insulin (0.34 ± 0.15 vs 0.36 ± 0.16 ng/mL) levels.

Insulin Receptor

Although a tendency toward a decrease of insulin receptor mRNA expression was noted (20% less), these changes did not achieve statistical significance (Figure 1).

Figure 1

Insulin receptor mRNA expression in skeletal muscle of SHAM (n = 14) and IUGR rats (n = 8)

Insulin receptor mRNA expression in skeletal muscle of SHAM (n = 14) and IUGR rats (n = 8). Transcripts were measured by real-time RT-PCR using appropriate primers and normalized to 18S mRNA. Data are expressed as relative quantification vs. SHAM group (RQ = 1). Bars represent standard errors.

Immunoblot analysis indicated a significant down regulation of insulin receptor in skeletal muscle of IUGR animals when compared with SHAM (control) (p < 0.05, Figure 2).

Figure 2

Insulin receptor beta subunit protein expression in skeletal muscle of SHAM (n = 14) and IUGR rats (n = 8) on day 0

Insulin receptor beta subunit protein expression in skeletal muscle of SHAM (n = 14) and IUGR rats (n = 8) on day 0. A, Western immunoblotting analysis; B, densitometric analysis.*P < 0.05.

Expression of LCFA metabolism regulatory enzymes

LCFAs act as nutrient abundance signals in the muscle. The expression of key enzymes that regulate muscle LCFA metabolism was assessed. The expression of ACCα and ACS mRNA levels was significantly reduced (by 54% and 66% respectively, p < 0.05) in skeletal muscle of IUGR rats at birth (Figure 3), whereas no significant differences in the expression of ACCβ, AMPK, and MCD were observed. Expression of muscle specific CPT1B was measured by quantitative RT-PCR but no significant difference between IUGR and SHAM pups was found.

Figure 3

Expression of acetyl-CoA carboxylase isoenzyme alpha (ACCα) and beta (ACC β), acyl-CoA synthase (ACS), AMP-activated protein kinase (AMPK), carnitine palmitoyltransferase-1 isoenzyme B (CPT1B), malonyl-CoA decarboxylase (MCD), in IUGR rat skeletal muscle. Transcripts were measured by real-time RT-PCR using appropriate primers and normalized to 18S mRNA. Data are expressed as relative quantification vs. SHAM group (RQ = 1). Bars represent standard errors. *P < 0.05.

ACCα immunoblotting analysis showed no differences between IUGR and SHAM animals thus suggesting a post-transcriptional regulation (Figure 4). ACS immunoblotting analysis couldn't be performed for unavailability of the specific antibodies.

Figure 4

Acetyl-CoA carboxylase isoenzyme alpha (ACCα) protein expression in skeletal muscle of SHAM (n = 14) and IUGR rats (n = 8) on day 0

Acetyl-CoA carboxylase isoenzyme alpha (ACCα) protein expression in skeletal muscle of SHAM (n = 14) and IUGR rats (n = 8) on day 0. A, western immunoblotting analysis; B, densitometric analysis.

Discussion

Uteroplacental insufficiency limits availability of substrates to the fetus and retards growth during gestation, ultimately leading to IUGR. Alterations in the intrauterine milieu have a profound impact on glucose homeostasis in the offspring, culminating in the development of insulin resistance, glucose intolerance and type 2 diabetes in adulthood.

The etiology of insulin resistance within skeletal muscle in the human with type 2 diabetes is multifactorial, involving impairments in hormonal signaling, enzyme and transporter activity, and substrate availability. Previous studies also implicated decreased oxidative capacities of skeletal muscle of human diabetics as contributory to insulin resistance 16.

To investigate the effects of uteroplacental insufficiency on the expression of insulin receptor in muscle, we studied an animal model of intrauterine growth retardation obtained by bilateral uterine artery ligation. In this model, the resulting uteroplacental insufficiency leads to growth retarded fetuses with a metabolic profile very similar to that of IUGR human fetuses 89. These animals exhibit impaired oxidative phosphorylation in skeletal muscle 17, mild peripheral insulin resistance and β-cell secretory defects very early in life but have adequate compensatory insulin secretion for several weeks 18. However, eventually, β-cell compensation fails, and overt diabetes occurs at age 3–6 months 9. More recently, it has been described in the same animal model that ligated offspring showed impaired glucose tolerance from the age of 15 weeks as well as elevated glycosylated hemoglobin and corticosterone levels 19.

Our data show for the first time reduced protein levels of insulin receptor in skeletal muscle of IUGR animals. The lack of statistical significance in insulin receptor mRNA expression is probably due to the relative low number of examined samples. Most of previous studies focused on downstream effectors of insulin actions in peripheral tissues without determining insulin receptor expression. In rat model, Ozanne et al. 20 showed that maternal protein restriction leads to muscle insulin resistance. Soleus muscle from growth restricted offspring had similar basal glucose uptakes compared with the control group, but whilst insulin stimulated glucose uptake into control muscle, it had no effect on growth restricted offspring muscle. This impaired insulin action was not related to changes in expression of either the insulin receptor or glucose transporter 4 (GLUT4). However, growth restricted offspring muscle expressed significantly less of the zeta isoform of protein kinase C (PKC ζ) compared with controls. This PKC isoform has been shown to be positively involved in GLUT4-mediated glucose transport. We have used a different model of intrauterine growth restriction based upon uterine artery ligation in which blood flow to the fetus is not ablated but reduced to a similar degree to that observed in human pregnancies complicated by uteroplacental insufficiency. Furthermore, whilst Ozanne et al. 20 studied 15-month-old animals, we investigated rats at birth. The use of only hind limb skeletal muscle might represent a limiting factor since an important difference between type 1 (slow) and type 2 (fast) fibers could exist. However, at birth it is practically impossible to select muscle fibers.

In humans, Jaquet et al. 21 demonstrated that insulin resistance is associated with an impaired regulation of GLUT4 gene expression by insulin in IUGR-born subjects in both skeletal muscle and adipose tissue.

Impairment of muscle fat metabolism is highly associated with insulin resistance. Our study shows for the first time that uteroplacental insufficiency leads to reduced ACS and ACCα mRNA expression in skeletal muscle at birth. In intramuscular lipid metabolism, ACS is the key enzyme for converting free fatty acids into LCFA-CoA. ACC catalyzes the formation of malonyl-CoA, an essential substrate for fatty acid synthesis in lipogenic tissues and a key regulatory molecule in muscle, brain, and other tissues 22. Three CPT1 isoforms with various tissue distributions and encoded by distinct genes have been identified: liver (CPT1A) 23, muscle (CPT1B) 24, and brain (CPT1C) 25 Cellular levels of malonyl-CoA repress CPT1 activity and decrease LCFA-CoAs oxidation. Therefore, the final effect of reduced expression of both ACS and ACCα would be the decrease of intramuscular LCFAs. This finding is consistent with our recent study in hypothalamus of IUGR rats, showing significant decreased ACCα and ACCβ expression at birth 10. Taken together these findings suggest that intrauterine programming may affect key enzymes of lipid metabolism at multiple levels. In muscle, however, ACCα protein content was not affected thus suggesting post-transcriptional regulation.

Lipids are implicated in the development of insulin resistance in skeletal muscle. This seems to be linked to an imbalance between lipid supply and lipid oxidation, the latter being related to decreased mitochondrial oxidative capacity in states of insulin resistance 26. In humans, it has been described that during physiological hyperglycemia with hyperinsulinemia and maintained FFA concentrations (i.e., a condition that mimics the insulin-resistant state), human skeletal muscle malonyl-CoA concentrations are significantly increased and are directly associated with a reduction in LCFA oxidation and functional CPT-1 activity 27.

As LCFA oxidative capacity in mitochondria is low in subjects with insulin resistance 202829303132, mitochondrial dysfunction and thereby decreased lipid oxidation has been considered to play a key role in the development of insulin resistance. Lane et al. reported an increase in triglyceride levels in IUGR rats 33 Accordingly, a connection between mitochondrial dysfunction, increased intramuscular triacylglycerol levels, and insulin resistance has been described in insulin-resistant offspring of patients with type 2 diabetes 34.

LCFAs may influence glucose metabolism by multiple mechanisms. LCFAs inhibit hexokinase activity 35 thus reducing glucose metabolism. They are also a substrate for the synthesis of ceramide which is increased in muscle of insulin-resistant rats 36. LCFAs may interfere with insulin signaling by activating protein kinase C. PKC in turn inhibits insulin signaling by phosphorylation of the serine residues on the insulin receptor 3738 and insulin receptor substrate-1 (IRS-1) 39, thus inhibiting the tyrosine phosphorylation of IRS-1. Patients with type 2 diabetes have increased PKC protein levels in the rectus abdominal muscle 40 and decreased muscle insulin receptor tyrosine kinase activity, which could be restored by phosphatase treatment in vitro, possibly suggesting increased serine phosphorylation of the insulin receptor due to increased PKC activity 37.

We speculate that intrauterine limited supply of substrates secondary to uteroplacental insufficiency may lead to down regulation of insulin receptor in skeletal muscle. We hypothesize that reduced intramuscular content of LCFAs secondary to reduced expression of both ACS and ACC may represent a transient compensatory mechanism to counteract insulin resistance during early postnatal life.

Conclusion

Uteroplacental insufficiency may affect skeletal muscle metabolism down regulating insulin receptor and reducing the expression of key enzymes involved in LCFA formation and oxidation. We speculate that decreased intramuscular lipid accumulation may represent a transient compensatory mechanism to counteract insulin resistance.

Abbreviations

ACC: acetyl-CoA carboxylase; ACS: acyl-CoA synthase; AMPK: AMP-activated protein kinase; CPT1: carnitine palmitoyltransferase-1; IUGR: intrauterine growth retardation; LCFA: long-chain fatty acid; MCD: malonyl-CoA decarboxylase.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DG: participated in the design of the study, carried out the experiments, performed statistical analysis and reviewed the manuscript. AP: carried out the experiments and reviewed the manuscript. SC: conceived the study, supervised the project and drafted the manuscript. He is the corresponding Author of the paper. All Authors read and approved the final manuscript.

Weight in infancy and death from ischaemic heart disease Barker DJ Winter PD Osmond C Margetts B Simmonds SJ Lancet 1989 2 577 580 10.1016/S0140-6736(89)90710-1 2570282 Growth <it>in utero</it>, blood pressure in childhood and adult life, and mortality from cardiovascular disease Barker DJ Osmond C Golding J Kuh D Wadsworth ME BMJ 1989 298 564 567 2495113 1835925 Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidemia (syndrome X): relation to reduced fetal growth Barker DJ Hales CN Fall CH Osmond C Phipps K Clark PM Diabetologia 1993 36 62 67 10.1007/BF00399095 8436255 Fetal origins of coronary heart disease Barker DJ BMJ 1995 311 171 174 7613432 Early growth and coronary heart disease in later life: a longitudinal study Eriksson JG Forsen T Tuomilehto J Osmond C Barker DJ Br Med J 2001 322 949 953 10.1136/bmj.322.7292.949 Insulin sensitivity in children born small for gestational age (SGA) Geremia C Cianfarani S Rev Diabet Stud 2004 1 58 65 1783541 17491667 10.1900/RDS.2004.1.58 Endocrine and metabolic programming during intrauterine development Fowden AL Giussani DA Forhead AJ Early Hum Dev 2005 81 723 734 10.1016/j.earlhumdev.2005.06.007 16085373 Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) and hepatic mRNA are increased in the small for gestational age fetal rat Unterman T Lascon R Gotway M Oehler D Gounis A Simmons RA Ogata ES Endocrinology 1990 127 2035 2037 1698152 Intrauterine growth retardation leads to the development of type 2 diabetes in rat Simmons RA Templeton LJ Gertz SJ Diabetes 2001 50 2279 2286 10.2337/diabetes.50.10.2279 11574409 Changes in the expression of hypothalamic lipid sensing genes in rat model of intrauterine growth retardation (IUGR) Puglianiello A Germani D Antignani S Scalia Tomba G Cianfarani S Pediatr Res 2007 61 433 437 10.1203/pdr.0b013e3180332d4e 17515867 Hyperglycemia normalizes insulin stimulated skeletal muscle glucose oxidation and storage in non insulin dependent diabetes mellitus Kelley DE Mandarino LJ J Clin Invest 1990 86 1999 2007 329837 2123890 10.1172/JCI114935 Effects of obesity and NIDDM on glucose and insulin regulation of substrate oxidation in skeletal muscle Mandarino LJ Consoli A Kelley DE Am J Physiol 1996 270 E463 E470 8638694 Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance Kelley DE Goodpaster BH Diabetes Care 2001 24 933 941 10.2337/diacare.24.5.933 11347757 Skeletal muscle triglyceride levels are inversely related to insulin action Pan DA Lillioja S Kriketos AD Milner MR Baur LA Bogardus C Jenkins AB Storlien LH Diabetes 1997 46 983 988 10.2337/diabetes.46.6.983 9166669 Perturbed skeletal muscle insulin signaling in the adult female intrauterine growth-restricted rat Oak SA Tran C Pan G Tramotharan M Devaskar SU Am J Physiol Endocrinol Metab 2006 290 E1321 E1330 10.1152/ajpendo.00437.2005 16449300 Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM Simoneau J-A Kelley DE J Appl Physiol 1997 83 166 171 9216960 IUGR alters postnatal rat skeletal muscle peroxisome proliferator-activated receptor-γ coactivator-1 gene expression in a fiber specific manner Lane RH Maclennan NK Daood MJ Hsu JL Janke SM Pham TD Puri AR Watchko JF Pediatr Res 2003 53 994 1000 10.1203/01.PDR.0000064583.40495.51 12646730 Impaired oxidative phosphorylation in skeletal muscle of intrauterine growth-retarded rats Selak MA Storey BT Peterside I Simmons RA Am J Physiol Endocrinol Metab 2003 285 E130 E137 12637257 Uteroplacental insufficiency after bilateral uterine artery ligation in the rat: impact on postnatal glucose and lipid metabolism and evidence for metabolic programming of the offspring by sham operation Nusken K-D Dotsch J Rauh M Rascher W Schneider H Endocrinology 18063678 Early growth restriction leads to down regulation of protein kinase C zeta and insulin resistance in skeletal muscle Ozanne SE Olsen GS Hansen LL Tingey KJ Nave BT Wang CL Hartil K Petry CJ Buckley AJ Mosthaf-Seedorf L J Endocrinol 2003 177 235 241 10.1677/joe.0.1770235 12740011 Impaired regulation of glucose transporter 4 gene expression in insulin resistance associated with in utero malnutrition Jaquet D Vidal H Hankard R Czernichow P Levy-Marchal C J Clin Endocrinol Metab 2001 86 3266 3271 10.1210/jc.86.7.3266 11443199 Regulation of acetyl-CoA carboxylase Brownsey RW Boone AN Elliott JE Kulpa JE Lee WM Biochem Soc Trans 2006 34 223 227 10.1042/BST20060223 16545081 Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene Britton CH Schulz RA Zhang B Esser V Foster DW McGarry JD Proc Natl Acad Sci USA 1995 92 1984 1988 42407 7892212 10.1073/pnas.92.6.1984 Isolation and characterization of cDNA and genomic clones encoding human muscle type carnitine palmitoyltransferase I Yamazaki N Shinohara Y Shima A Yamanaka Y Terada H Biochim Biophys Acta 1996 1307 157 161 8679700 A novel brain-expressed protein related to carnitine palmitoyltransferase I Price N Leij van der F Jackson V Corstorphine C Thomson R Sorensen A Zammit V Genomics 2002 80 433 442 10.1006/geno.2002.6845 12376098 Skeletal muscle lipid metabolism in exercise and insulin resistance Kiens B Physiol Rev 2006 86 205 243 10.1152/physrev.00023.2004 16371598 Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle Rasmussen BB Holmbäck UC Volpi E Morio-Liondore B Paddon-Jones D Wolfe RR J Clin Invest 2002 110 1687 1693 151631 12464674 Skeletal muscle utilization of free fatty acids in women with visceral obesity Colberg SR Simoneau JA Thaete FL Kelley DE J Clin Invest 1995 95 1846 1853 295723 7706491 10.1172/JCI117864 Intramuscular lipid content is increased in obesity and decreased by weight loss Goodpaster BH Theriault R Watkins SC Kelley DE Metabolism 2000 49 467 472 10.1016/S0026-0495(00)80010-4 10778870 Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes Kelley DE He J Menshikova EV Ritov VB Diabetes 2002 51 2944 2950 10.2337/diabetes.51.10.2944 12351431 Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes Ritov VB Menshikova EV He J Ferrell RE Goodpaster BH Kelley DE Diabetes 2005 54 8 14 10.2337/diabetes.54.1.8 15616005 Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss Simoneau JA Veerkamp JH Turcotte LP Kelley DE FASEB J 1999 13 2051 2060 10544188 Altered expression and function of mitochondrial beta-oxidation enzymes in juvenile intrauterine-growth-retarded rat skeletal muscle Lane RH Kelley DE Ritov VH Tsirka AE Gruetzmacher EM Pediatr Res 2001 50 83 90 10.1203/00006450-200107000-00016 11420423 Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes Petersen KF Dufour S Befroy D Garcia R Shulman GI N Engl J Med 2004 350 664 671 10.1056/NEJMoa031314 14960743 Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance Thompson AL Cooney GJ Diabetes 2000 49 1761 1765 10.2337/diabetes.49.11.1761 11078441 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo Turinsky J O'Sullivan DM Bayly BP J Biol Chem 1990 265 16880 16885 2211599 Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity Itani SI Zhou Q Pories WJ MacDonald KG Dohm GL Diabetes 2000 49 I1353 1358 10.2337/diabetes.49.8.1353 Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity Takayama S White MF Kahn CR J Biol Chem 1988 263 3440 3447 3125181 Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin Ravichandran LV Esposito DL Chen J Quon MJ J Biol Chem 2001 276 3543 3549 10.1074/jbc.M007231200 11063744 Increased protein kinase C theta in skeletal muscle of diabetic patients Itani SI Pories WJ MacDonald KG Dohm GL Metabolism 2001 50 553 557 10.1053/meta.2001.22512 11319716